RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

NCT01259063 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Everolimus and Intravesical Gemcitabine

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]